SRPT (Sarepta Therapeutics Inc.) stock: $20.11, $2.12B market cap, $788.5M cash, $2.18B EV, $2.54B fully diluted market cap. Next expected readout: Oct-26. Lead program: Eteplirsen (Muscular Dystrophy, Duchenne), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$2,183.3M
Balance sheet
| Cash | $788.5M |
|---|
| Debt | $847.6M |
|---|
| Net cash | -$59.1M |
|---|
| Enterprise value | $2,183.3M |
|---|
| Basic shares | 105.6M shares |
|---|
| Fully diluted shares | 126.4M shares |
|---|
| Fully diluted market cap | $2,542.4M |
|---|
| Cash per share | $7.47 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading SRPT daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Dec 12, 2026 - Jan 23, 2027 | Eteplirsen | Phase 3 | Muscular Dystrophy, Duchenne | — |
| Feb 11 - Mar 25 | SRP-1003 IV Infusion | Phase 2 | Myotonic Dystrophy 1 | — |
| Jan 11 - Feb 22 | SRP-1005 | Phase 1 | Huntington's Disease | — |
| Feb 11 - Mar 25 | SRP-1001 for Injection | Phase 2 | Muscular Dystrophy, Facioscapulohumeral | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
SRP-1003
Phase 1 · Active Modality: siRNA knockdown
Target DMPK
Partnerships Arrowhead Pharmaceuticals: collaboration (annual license fees of $50M; up to $10.3B in development/regulatory/sales milestones; DM1 milestones achieved 2025)
Indications- Myotonic dystrophy type 1 (Phase 1)
Status note Phase 1/2 trial conducted to date by Arrowhead; Sarepta transitioning sponsorship to itself. Early results shared March 2026.
SRP-1001
Phase 1 · Active Modality: siRNA (RNAi) knockdown
Target DUX4
Partnerships Arrowhead Pharmaceuticals: collaboration
Indications- Facioscapulohumeral muscular dystrophy (Phase 1)
Status note Phase 1/2 trial conducted to date by Arrowhead; Sarepta transitioning sponsorship to itself. Early results shared March 2026.
SRP-1005
Phase 1 · Active Modality: subcutaneous siRNA (TfR1 fAb-mediated CNS delivery)
Target HTT
Indications- Huntington's disease (Phase 1)
Status note INSIGHTT Phase 1 dose-escalation study (~24 participants); first patient enrolled Q2 2026.
ELEVIDYS (delandistrogene moxeparvovec-rokl)
Approved · Active Modality: AAV gene therapy
Target DMD
Partnerships Roche: ex-US rights and commercialization
Indications- Duchenne muscular dystrophy (ambulatory) (Stage not disclosed)
- Duchenne muscular dystrophy (non-ambulatory) (Stage not disclosed)
Status note Traditional FDA approval (June 2024) for ambulatory patients >=4 years; accelerated approval for non-ambulatory patients (June 2024). Shipments to non-ambulatory patients suspended June 2025; November 2025 boxed warning for acute liver injury/acute liver failure and removal of non-ambulatory population from label. Sirolimus enhanced-immunosuppression study (ENDEAVOR Cohort 8) ongoing to support pathway for resuming non-ambulatory dosing.
SRP-9003
Phase 3 · Active Modality: AAV gene therapy
Aliases bidridistrogene xeboparvovec
Target SGCB
Indications- LGMD2E (beta-sarcoglycanopathy) (Phase 3)
Status note EMERGENE Phase 3 completed enrollment and dosing December 2024; safety and expression results announced October 2025. FDA clinical hold (July 2025, confirmed December 2025) on investigational LGMD gene therapy trials; BLA acceptance for SRP-9003 requires sirolimus immunosuppressant data first. Other LGMD programs (SRP-9004, SRP-6004, SRP-9005) suspended in July 2025 restructuring.
SRP-9004 / SRP-6004 / SRP-9005
Stage not disclosed · Terminated Modality: AAV gene therapy
Indications- LGMD2D/R4 (Stage not disclosed)
- LGMD2B/R2 (Stage not disclosed)
- LGMD2C/R5 (Stage not disclosed)
Status note Suspended as part of July 2025 restructuring (following FDA clinical hold after a patient death in the SRP-9004 Phase 1 trial); only SRP-9003 continues.
AMONDYS 45 / VYONDYS 53
Approved · Active Modality: PMO (phosphorodiamidate morpholino oligomer)
Target DMD
Indications- Duchenne muscular dystrophy (exon 45 amenable) (Stage not disclosed)
- Duchenne muscular dystrophy (exon 53 amenable) (Stage not disclosed)
Status note November 2025 confirmatory ESSENCE trial missed its primary endpoint; sNDAs submitted April 2026 and accepted for filing June 2026; FDA discussions on pathway forward ongoing.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.